Skip to main
COYA
COYA logo

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics Inc is strategically positioned to capitalize on its innovative approach to developing proprietary Treg therapies for complex diseases, which aligns with the growing demand for specialized treatments in biotechnology. The company's financial trajectory reflects a robust growth pattern, highlighted by an impressive increase in library revenues, suggesting a strong demand for its unique content portfolio. Furthermore, the anticipated recovery in television production and the shift towards a tentpole-driven slate are expected to enhance profitability in the coming years, indicating a positive future outlook for the company's financial health.

Bears say

Coya Therapeutics is facing a negative outlook primarily due to significant year-over-year revenue declines, driven by fewer theatrical releases and a poor performance in prior year film slates. The company's second-quarter revenues fell to $199 million, markedly down from $417 million in the same quarter the previous year, indicating challenges related to delivery timings and content production inefficiencies. Additionally, the requirement to rebuild its content pipeline poses risks to cash flow and elevates concerns regarding its leverage profile, which could hinder future financial stability.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.